Challenges of cancer therapy with natural killer cells

Cytotherapy

Volumn 17, Issue 3, 2015, Pages 245-249

  Klingemann, Hans ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; CAR; Cell expansion; Cell therapy; Cryopreservation; Natural killer cells

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; HLA ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; HLA ANTIGEN CLASS 1;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER IMMUNOTHERAPY; CELL EXPANSION; CRYOPRESERVATION; DONOR SELECTION; EPSTEIN BARR VIRUS INFECTION; GENETIC ENGINEERING; HEMOLYSIS; HUMAN; LEUKAPHERESIS; LEUKEMIA REMISSION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T CELL DEPLETION; ADOPTIVE IMMUNOTHERAPY; BIOLOGICAL THERAPY; CELL CULTURE TECHNIQUE; CELL LINE; CYTOLOGY; FETUS BLOOD; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; NEOPLASMS; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; CELL CULTURE TECHNIQUES; CELL LINE; CELL- AND TISSUE-BASED THERAPY; CRYOPRESERVATION; FETAL BLOOD; GENETIC ENGINEERING; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTES;

EID: 84925079009     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.09.007     Document Type: Review

References (32)

1. Lanier L.L. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008, 9:495-502.
2. Khuu H., Betters D.M., Cook L. Adoptive transfer of escalating doses of ex vivo expanded autologous Natural Killer (NK) cells In patients with advanced malignancies following bortezomib treatment to sensitize to NK-TRAIL cytotoxicity. Blood 2010, 116:4296.
3. Burns L.J., Weisdorf D.J., DeFor T.E., Vesole D.H., Repka T.L., Blazar B.R., et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant 2003, 32:177-186.
4. Boissel L., Betancur M., Lu W., Wels W.S., Marino T., Van Etten R.A., et al. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma 2012, 53:958-965.
5. Ruggeri L., Campanni M., Casucci M., Volpi I., Tosti A., Perruccio K., et al. Role of natural killer cell alloreactivity in HLA -mismatched hematopoietic stem cell transplantation. Blood 1999, 94:333-339.
6. Bari R., Rujkiyanont P., Sullivan E., Kang G., Turner V., Gan K., et al. Effect of donor KIRDL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation. JClin Oncol 2013, 31:3782-3790.
7. Cooley S., Weisdorf D.J., Guethlein L.A., Klein J.P., Wang T., Le C., et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-2419.
8. Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T., et al. NKAML: A pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. JClin Oncol 2010, 28:955-959.
9. Bachanova V., Cooley S., Defor T.E., Veneris M.R., Zhang B., McKenna D.H., et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 2014, 123:3855-3863-7.
10. McKenna D.H., Sumstad D., Bostrom N., Kadidlo D.M., Fautsch S., McNearney S., et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six year single-institution experience. Transfusion 2007, 47:6079-6086.
11. Koepsell S.A., Miller J.S., McKenna DH Natural killer cells: a review of manufacturing and clinical utility. Transfusion 2012, 53:404-410.
12. Klingemann H., Grodman C., Cutler E., Duque M., Kadidio D., Klein A.K., et al. Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell enriched infusions. Transfusion 2013, 53:412-418.
13. Shimasaki N., Fujisaki H., Cho D., Masselli M., Lockey T., Eldridge P., et al. Aclinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 2012, 14:830-840.
14. Spanholtz J., Preijers F., Tordoir M., Trilsbeek C., Paardekooper J., de Witte T., et al. Generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PloS ONE 2011, 6:e20740.
15. Koehl U., Brehm C., Huenecke S., Zimmermann S.-Y., Kloess S., Bremm M., et al. Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Med 2013, 3:1-12.
16. Lapteva N., Durett A.G., Sun J., Rollins L., Dandekar V., Mei Z., et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical application. Cytotherapy 2012, 14:1131-1143.
17. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. NEngl J Med 2011, 365:755-763.
18. Maus M.V., Grupp S.A., Porter D.L., June C.H. Antibody-modified T-cells: CARs take the front seat for hematologic malignancies. Blood 2014, 123:2625-2635.
19. Klingemann H. Are NK cells superior CAR drivers. OncoImmunology 2014, 3:e28147.
20. Woll P.S., Grzywacz B., Tian X., Marcus R.K., Knorr D.A., Verneris M.R., et al. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with highly potent in vivo anti-tumor activity. Blood 2009, 113:6094-6101.
21. Klingemann H-G. Development and testing of NK cell lines. In: Lotze MT, Thompson AW (eds): Natural killer cells - Basic Science and Clinical applications. London: Elseiver Ltd; 2010. p. 169-75.
22. Visonneau S., Cesano A., Porter D.L., Luger S.L., Schuchter L., Kamoun M., et al. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clin Cancer Res 2000, 6:1744-1755.
23. Yagita M., Huang C., Umehara H., Matsuo Y., Tabata R., Miyake M., et al. Anovel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 2000, 14:922-930.
24. Swift B.E., Williams B.A., Kosaka Y., Wang X.-H., Medin J.A., Viswanathan S., et al. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica 2012, 97:1020-1028.
25. Gong J.H., Maki G., Klingemann H.G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994, 8:652-658.
26. Maki G., Klingemann H.G., Martinson J.A., Tam Y.K. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. JHematother Stem Cell Res 2001, 10:369-383.
27. Arai S., Meagher R., Swearingen M., Myint H., Rich E., Martinson J., et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma - A phase I trial. Cytotherapy 2008, 10:625-632.
28. Tonn T., Schwabe D., Klingemann H., Becker S., Esser R., Koehl U., et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 2013, 15:1563-1570.
29. Lehmbecher T., Foster C.B., Zhu S., Leitman S.F., Goldin L.R., Huppi K., et al. Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low affinity Fcy receptor polymorphism in control and disease populations. Blood 1999, 94:4220-4232.
30. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002, 99:754-758.
31. Zhang W., Gordon M., Schultheis A.M., Yang D.Y., Nagashima F., Azuma M., et al. FCGR2A and FCGT3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expressing metastatic colorectal cancer patients treated with single agent cetuximab. JClin Oncol 2007, 25:3712-3718.
32. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Cappelleti M., Missale G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with Her-2/neu positive metastatic breast cancer. JClin Oncol 2008, 26:1789-1796.